The Rise of Intellectual Property Commercialization in the 20th Century

Ideas have always had value – but for most of history, that value was poorly understood and even more poorly protected. The 20th century changed everything. Over the course of a hundred years, intellectual property transformed from a relatively obscure legal concept into one of the most powerful drivers of economic growth, industrial competition, and global trade. Patents, copyrights, trademarks, and trade secrets stopped being just defensive shields for inventors – they became strategic commercial assets in their own right. Understanding how this shift happened is essential for anyone studying IP law today, because the commercialization frameworks built during this era form the backbone of the legal systems we still operate under.

From lone inventors to organized innovation 🔗

The early 20th century inherited a model of invention that was already beginning to crack under its own limitations. Thomas Edison’s Menlo Park laboratory, established in the late 19th century, had already demonstrated something radical: invention did not have to be accidental or solitary. It could be organized, funded, and directed toward commercially viable outputs. Edison believed in inventing only what the market needed, and his laboratory was explicitly designed to generate a steady flow of patentable products.

Edison’s model inspired a wave of corporate research laboratories across the United States and Europe. By 1940, there were over 1,000 industrial research labs operating in the U.S. alone, employing scientists from companies like DuPont, General Electric, Westinghouse, and RCA. These were not informal workshops – they were structured environments where intellectual work was professionalized, and where patent production was an explicit goal. The sharp cultural divide that had previously existed between “pure” scientists and commercial inventors began to dissolve. Scientists were now employees, and their discoveries were assets belonging to the corporations that employed them.

This shift had profound legal implications. The ownership of intellectual property moved away from individual inventors and toward corporations. Employment contracts routinely included IP assignment clauses, meaning that innovations created on the job belonged to the employer. This institutional ownership model meant that companies could accumulate large portfolios of patents, which they could then use strategically – to block competitors, cross-license with rivals, or generate royalty income.

Bell Labs: the blueprint for IP-driven innovation 🔗

Bell Telephone Laboratories, formally established in 1925, became the defining example of how a corporation could turn sustained investment in research into commercial and competitive dominance. Backed by AT&T’s monopoly revenues, Bell Labs employed thousands of scientists and engineers who worked on everything from basic physics to practical telecommunications engineering. The results were extraordinary: researchers at Bell Labs are credited with the invention of the transistor, the laser, the solar cell, and information theory, among dozens of other foundational technologies. Over its lifetime, Bell Labs accumulated more than 17,000 patents.

What made Bell Labs significant for IP commercialization was not just the volume of innovation, but the deliberate use of patents as instruments of market control and revenue generation. AT&T used its patent portfolio to shape the telecommunications industry, licensing technologies strategically and using IP protection to maintain its dominant position. When antitrust authorities forced AT&T to license its non-telecoms patents on a no-fee basis in the 1950s, the resulting diffusion of Bell Labs technology – including the transistor – provided the foundation for an entire generation of innovations in semiconductors, computing, and consumer electronics. Even in forced licensing, the IP had enormous commercial consequences.

IBM and Texas Instruments both consciously modeled their own research operations on Bell Labs, recognizing that structured investment in intellectual capital could yield competitive advantages far beyond what any single product could provide. IBM, in particular, would later build one of the most profitable patent licensing programs in the world, generating revenue from its IP portfolio independent of its product sales.

Patents as commercial strategy: the pharmaceutical industry 🔗

No sector illustrates the commercial logic of 20th-century IP law more clearly than pharmaceuticals. As antibiotic research took off in the mid-century, drug companies discovered that patent protection could justify the enormous cost and risk of drug development. A company willing to invest millions in research for a compound that might fail could only rationally do so if it had a guarantee of exclusive commercial exploitation for a limited period. Patents provided precisely that guarantee.

The pharmaceutical patent model that emerged in the 20th century became a template for high-risk, high-return industries worldwide. Companies would patent not just the active compound but manufacturing processes, delivery mechanisms, and formulations – creating layered protections that extended effective market exclusivity. This approach shaped global drug pricing, access debates, and eventually the TRIPS Agreement of 1995 under the World Trade Organization, which harmonized patent standards across member nations and embedded pharmaceutical IP protection into international trade law.

For Indian students of IP law, this history is particularly relevant. India’s own patent landscape was deeply shaped by these global developments. India enacted its Patents Act in 1970, which deliberately excluded product patents for food, chemicals, and pharmaceutical substances – a policy designed to allow domestic manufacturers to produce affordable medicines. This position put India at odds with the TRIPS framework, eventually leading to significant amendments in 2005 that brought India into compliance with international patent norms, reshaping its pharmaceutical industry in the process.

The rise of licensing as a business model 🔗

One of the most significant commercial innovations of the 20th century was the recognition that intellectual property did not need to be embodied in a product to generate revenue. Licensing emerged as a standalone business strategy, allowing IP owners to extract value from their assets without manufacturing anything themselves.

Universities were slow to adopt this model, but the transformation eventually came. The U.S. Bayh-Dole Act of 1980 was a landmark in this regard. Before this legislation, federally funded research in universities generated inventions that were owned by the government – and of approximately 28,000 such patents, fewer than 5% were ever commercially licensed. The Act transferred ownership rights to universities, requiring them to actively pursue commercialization through licensing. The results were dramatic: since its enactment, Bayh-Dole has contributed to over $1.3 trillion in U.S. economic growth, more than 4.2 million jobs, and over 11,000 university-linked startups. University patenting itself increased tenfold in the decades following the Act’s passage.

This shift formalized the idea that knowledge produced in academic settings had commercial value that could and should be harnessed. Technology transfer offices became standard features of research universities. The relationship between academia, industry, and government shifted from one of separate spheres to an interlocking system where IP was the currency of exchange.

Copyright and the entertainment economy 🔗

While patents dominated industrial IP commercialization, copyright underwent its own commercial revolution in the 20th century, driven primarily by new communication technologies. Radio, cinema, and later television created entirely new markets for creative works and entirely new legal questions about how those works could be distributed, reproduced, and monetized.

Courts grappled with the commercial dimensions of information throughout the century, developing doctrines around misappropriation and proprietary rights in content that had no obvious physical form. The 1918 U.S. Supreme Court case of International News Service v. Associated Press established early principles around the commercial value of information and the rights of its producers – principles that remain relevant in the digital age.

By mid-century, major entertainment companies had learned to treat creative IP as a portfolio of commercial assets rather than a collection of individual works. Merchandise licensing, character franchising, and syndication rights turned copyrights into multi-layered revenue streams. This commercialization of creative IP eventually demanded stronger international protection, leading to the strengthening of the Berne Convention framework and its eventual integration into the TRIPS Agreement.

The global framework takes shape: WIPO and TRIPS 🔗

As IP commercialization grew in economic importance, so did the pressure for international harmonization. The Paris Convention (1883) and the Berne Convention (1886) had established early frameworks for cross-border IP protection, and their successor institutions eventually merged into the World Intellectual Property Organization (WIPO), established under the United Nations in 1967. WIPO provided an international forum for IP governance, but its frameworks were largely voluntary and uneven in enforcement.

The decisive shift came with the 1994 Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which came into force in 1995 as part of the World Trade Organization framework. TRIPS integrated IP rights into global trade law, making meaningful IP protection a condition of WTO membership. This meant that countries wanting access to international markets had to maintain patent, copyright, and trademark systems meeting minimum international standards – a profound expansion of IP commercialization as a global economic norm.

For developing nations, including India, TRIPS created both opportunities and tensions. Stronger IP protection could attract foreign investment and technology transfer. But it also meant higher costs for accessing patented technologies, particularly in pharmaceuticals. These tensions remain live legal and policy debates today, directly relevant to IP management as a field of study.

The professionalization of intellectual work 🔗

Perhaps the most enduring transformation of the 20th century was not any single law or institution, but a broader shift in how intellectual work itself was understood. Edison is credited with inventing the industrial research laboratory – the idea that innovation could be organized, staffed, and directed like any other business function. By century’s end, this had become the default model across industries. Research and development departments, corporate patent counsel, technology licensing officers, and IP valuation specialists all became established professional roles.

Intellectual property stopped being an afterthought in commercial strategy and became central to it. Companies were valued not just on their physical assets but on their patent portfolios, trademarks, and trade secrets. The commercialization of intangible assets – through licensing, sale, franchising, joint ventures, and startup formation – became a core function of corporate management. This is the world that modern IP law governs, and its roots lie firmly in the economic and legal transformations of the 20th century.

What do you think? The Bayh-Dole Act dramatically accelerated the commercialization of university research by giving institutions ownership over federally funded inventions – but critics argue it has also contributed to rising costs for essential medicines and technologies. Is the trade-off between incentivizing innovation and ensuring public access being struck in the right place? And given India’s distinct position in global IP law – particularly its 2005 amendments to align with TRIPS – do you think developing countries have enough flexibility within the current international framework to balance access with innovation?

References

1. https://americanaffairsjournal.org/2017/11/edisons-legacy-industrial-laboratories-innovation/
2. https://www.ebsco.com/research-starters/history/bell-labs-formed
3. https://en.wikipedia.org/wiki/Bell_Labs
4. https://worksinprogress.co/issue/the-rise-and-fall-of-the-american-rd-lab/
5. https://www.construction-physics.com/p/the-influence-of-bell-labs
6. https://www.upcounsel.com/intellectual-property-rights-history
7. https://ipindia.gov.in/patents.htm
8. https://techtransfer.syr.edu/about/bayh-dole/
9. https://www.aau.edu/key-issues/preserve-bayh-dole-act-and-university-technology-transfer
10. https://cyber.harvard.edu/property99/history.html
11. https://www.wipo.int/treaties/en/ip/berne/
12. https://www.wipo.int/about-wipo/en/
13. https://www.pnas.org/doi/10.1073/pnas.1404094111
14. https://www.bocoip.com/en/ipr-wiki/intellectual-property-rights-and-their-commercialization/